MAPK1 and neoplasm: Thus, the RAS-RAF-MEK-ERK pathway has become a critical target for anti-tumor therapy to the extent that the inhibition of mutant B-RAF (Val600→Glu) was found to be therapeutically efficacious [1] (see below).